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thrombus aspiration may prevent four deaths per thousand at the cost
of two strokes per thousand. Although this may initially sound
favorable for the procedure, the conﬁdence interval for mortality is
still wide enough to encompass no effect, while that of stroke is not.
With mortality now so low in STEMI trials, very large numbers of
patients are required to reliably identify a clinically important
improvement. The task requires massive multi-center trials or stra-
tegies that minimize per-patient costs by using established outcome-
reporting infrastructure to focus on mortality, and perhaps introduce
“retrospective consent”.
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BACKGROUND Several studies of acute myocardial infarction (MI)
have documented the prognostic importance of early post-MI infarct
size related to long-term outcomes such as mortality or heart failure
(HF). However, whether a change in infarct size due to an inter-
vention is related to the intervention’s effect on outcomes has not
been conclusively demonstrated. We used patient-level data from
acute MI primary PCI trials to assess the relation between short-term
effects on infarct size and longer-term effects on outcomes. We hy-
pothesized that a therapy-induced change in infarct size would be
related in direction and/or magnitude to the outcome effect of that
therapy.
METHODS We combined patient-level data from 10 randomized
clinical trials that tested various therapies for ST elevation MI
(STEMI). Infarct size was assessed by sestamibi imaging in 3 trials and
by cardiac magnetic resonance imaging in 7 trials, using standard
techniques with analysis in core labs, and was expressed as a % of left
ventricular (LV) mass. Each patient within a trial was assigned a
variable to represent that study treatment’s mean effect on infarct
size based on whether the patient was in the treatment or placebo
group. Cox proportional hazards models estimated the association of
treatment-related infarct size to one-year adjudicated clinical out-
comes of hospitalization for heart failure and all-cause mortality.
RESULTS The 10 trials included 2,458 patients, 24% women, 7% with
prior MI. Infarct size was measured at a median of 5 days post-MI.
Mean trial infarct size in the control groups in the 10 trials ranged from
12% - 35% of the LV, and from 12% - 40% among treatment groups.
There was a signiﬁcant relation of treatment effect on infarct size to
treatment effect on one-year HF hospitalization (HR 0.83, 95% CI 0.75
to 0.93, p<0.001). There was no signiﬁcant relation between treat-
ment effect on infarct size to treatment effect on one-year mortality
(HR 1.04, 95% CI 0.94 to 1.15). The relation to HF hospitalization was
stable in sensitivity analyses adjusting for time from MI to infarct size
assessment, and for considering HF as the main outcome and death as
a competing risk.
CONCLUSIONS This patient-level analysis of randomized placebo-
controlled trials of multiple therapeutics for STEMI suggests that a
treatment-induced effect on infarct size is related in direction and
quantiﬁable magnitude to a treatment effect on HF hospitalizations.
The data enable the consideration of incorporating infarct size assess-
ment into novel trial analytic approaches as a surrogate endpoint to
assess new therapeutics.
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BACKGROUND No reﬂow phenomenon is not uncommon in patients
with acute ST-segment elevation myocardial infarction (STEMI)
directly revascularized by PCI with immediate stenting (IS). We previ-
ously showed in a pilot study that a minimalist immediate mechanical
intervention (MIMI), based on the use of guidewire or undersized bal-
loons to avoid both large dissection and distal embolization, may be
sufﬁcient to restore ﬂow in emergency in most of patients with acute
STEMI and that recanalization may be sustained by optimized antith-
rombotic regimen allowing to postpone stenting in better conditions.
MIMI also allows to schedule more appropriate medical or surgical
alternative management when more suitable for the patient. We report
in the present study our experience in MIMI approach over 14 years.
METHODS From April 2001 to May 2015, among 2074 primary PCI per-
formed in our institution, 1591were done for a TIMI 0ﬂowof the infarct-
related artery (IRA) at admission coronary angiogram. The choice be-
tween IS and MIMI was done depending on presence of a large
thrombus, complex lesion (bifurcation), indication for urgent or semi-
urgent surgery, questionable signiﬁcant stenosis underlying thrombus.
RESULTS IS was performed in 950 cases. The guidewire or the balloon
failed to cross the lesion in 14 of the 1591patients (0.9%). Among the
remaining 627 cases in whom IS was not performed, once the infarct–
related artery had been recanalized usingMIMI, 483 cases underwent a
two-step strategy. The ﬁnal strategy was medical in 55 cases (10%),
surgery in 170 (35%) and deferred stenting (DS) in 258 (55%) at amean of
4  4 days after initial PCI. IRA reocclusion before ﬁnal strategy
occurred in 1% in all cases with post-MIMI TIMI 3 ﬂow and in 5 of the 17
cases (29%)with post-MIMI TIMI 2ﬂow. The rates of no-reﬂow andTIMI
3 ﬂow after stenting in the DS groupwere 0% and 98.4%, respectively vs
1.8%and91% in the IS group (p<0.001). Distal embolization occurred in
1.8% of the IS and in 0.4% in the DS group (¼0.19). The total rate of TIMI
ﬂow < 3 and distal embolization after stenting was 11% in the IS group
compared to 2% in the DS group (p < 0.0001).
CONCLUSIONS This study suggests that a two-step strategy for the
treatment of acute STEMI by PCI based on a MIMI approach with de-
ferred stenting is possible and seems to achieve better immediate
angiographic results than immediate stenting. However, if a two-step
strategy is applied, a TIMI 3 ﬂow is mandatory after MIMI to avoid
early reocclusion before the ﬁnal strategy.
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BACKGROUND Platelets play a central role in ST-segment elevation
myocardial infarction (STEMI) pathobiology and in the no-reﬂow
